Stock analysts at Noble Financial issued their FY2024 earnings per share (EPS) estimates for Gyre Therapeutics in a research report issued to clients and investors on Tuesday, March 11th. Noble ...

Noble Capital initiated coverage of Gyre Therapeutics (GYRE) with an Outperform rating. Gyre is developing drugs for inflammatory diseases that ...

SAN DIEGO—Ma Songjiang, President of Gyre Therapeutics, Inc. (NASDAQ:GYRE), a $1.03 billion market cap biotech company, executed sales of common stock valued at a total of $46,360 over two ...

S AN DIEGO—Ma Songjiang, President and Director of Gyre Therapeutics, Inc. (NASDAQ:GYRE), recently sold shares in the company totaling $45,434, according to a recent SEC filing. The transactions ...

3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Several large investors have recently bought and sold shares of GYRE. Geode Capital Management LLC ...

Over the last 7 days, the United States market has experienced a 3.7% decline, although it has shown a 6.9% increase over the past year with earnings projected to grow by 14% annually. In this context ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Addison Shea's project involving Bowhead whales under consideration for the oldest and most prestigious STEM prize for high school seniors in the U.S.

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated ...